Del Monte Corporation DMC
27.22 USD -0.39 (-1.41%)
Nov 10, 2026, 10:26 AM EST
27.05 Day range 27.60
26.09 52-week range 43.58
- YTD
- -23.60%
- 1 year
- -27.66%
News
globenewswire.com Good Protein Secures CA$128 Million and SEMCAP Partnership to Fuel Next Phase of Growth Protein shake maker Good Protein secures CA$128 million from SEMCAP Food & Nutrition and consortium of Canadian investors to fuel next phase of growth.
247wallst.com Buy, Sell, or Hold? Wednesday’s Top Upgrades and Downgrades: Adobe, Apple, Duolingo, Exxon Mobil, Fiserv, Fortinet, Gartner, Lockheed Martin, Skyworks Solutions, Visa and More Wall Street analysts shifted their stances on some of the market's most closely watched names Wednesday, with surprising cuts hitting stocks many investors still consider safe bets and fresh upgrades…
businesswire.com Del Monte Corporation to Participate in Stephens Annual Investment Conference CORAL GABLES, Fla.--(BUSINESS WIRE)--Del Monte Corporation to Participate in Stephens Annual Investment Conference.
benzinga.com Del Monte Sees FY2026 Adjusted Net Sales Growth of 13%-15%, Adjusted EBITDA of $230M-$240M Del Monte (NYSE:DMC) sees full-year adjusted net sales growth of 13%-15% and adjusted EBITDA of $230 million to $240 million.
benzinga.com Del Monte Q3 2026 Earnings Call Transcript Del Monte (NYSE:DMC) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Del Monte Q3 Adj. EPS $0.50 Beats $0.46 Estimate, Sales $1.095B Miss $1.159B Estimate Del Monte (NYSE:DMC) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.46 by 8.7 percent. This is a 27.54 percent decrease over earnings of $0.69 per…
benzinga.com Perfect Stock Portfolio: September 2026 Edition The past month has reminded us that international investing is never simply a matter of finding a cheap stock market and waiting for investors to notice. Politics, energy, trade policy, currencies,…- benzinga.com Reported Earlier, Del Monte Expands Into China’s Fresh-Cut Fruit Market Through Riverking Joint Venture Del Monte Corporation (NYSE:DMC), one of the world's leading vertically integrated producers, distributors and marketers of fresh and shelf-stable produce, today announced that its subsidiary, Del…
benzinga.com Perfect Stocks Portfolio: August 2026 Edition The past month has offered investors a useful reminder that financial markets rarely move in lockstep with the headlines. The geopolitical backdrop has become more difficult, trade policy remains…
benzinga.com Del Monte Reports Strong EPS Even With Revenue Pressure Del Monte beats second-quarter EPS estimates as acquisition-driven growth offsets weaker banana sales and fresh produce segment challenges.
benzinga.com Del Monte Q2 Adj. EPS $0.72 Beats $0.53 Estimate, Sales $1.219B Miss $1.305B Estimate Del Monte (NYSE:DMC) reported quarterly earnings of $0.72 per share which beat the analyst consensus estimate of $0.53 by 35.85 percent. This is a 41.46 percent decrease over earnings of $1.23 per…
benzinga.com UPDATE: Cantor Fitzgerald Initiates Buy, $12 PT on Vanguard Health Systems - benzinga.com Chelsea Therapeutics Achieves Target Enrollment in Phase II Trial of Droxidopa in Fibromyalgia
- benzinga.com Document Security Systems, Inc. Acquires Cloud Computing Company ExtraDev
benzinga.com Document Security Systems reports Q4 EPS of $(0.11) vs. $(0.04) 
benzinga.com Earnings Scheduled For March 29 (APOL, LNDC, MKC, REX, LEN, OXM, TIBX, ZZ, XNY, VIP, ACMR, DOVR, CTFO, DMC) - benzinga.com Document Security Systems Awarded Seventeen New Brand-Protection Technology Patents
- benzinga.com Document Security Systems, Inc. Signs Technology Licensing Agreement With Midwest Banknote Company
- benzinga.com Document Security Systems, Inc. Regains NYSE Amex Compliance
benzinga.com Document Security Systems, Inc. Receives $4 Million Equity Investment 
benzinga.com Gilead Ends Letairis Trial for IPF - Analyst Blog 
benzinga.com Gilead Ends Letairis Trial for IPF - Analyst Blog - benzinga.com Q&A Interview With Pharmaceutical Company, BioSante Pharmaceuticals (NASDAQ: BPAX)
- benzinga.com NASDAQ Biotech/Pharma Market Leaders; (NASDAQ:BPAX), (NASDAQ:AMGN), (NASDAQ:LIFE) Stocks to Follow for Wednesday
- benzinga.com NASDAQ Biotech Market Gainers; (BPAX), (CELG), (GILD) Stocks to Watch
- benzinga.com Q&A Interview with BioSante Pharmaceuticals (NASDAQ: BPAX)
- benzinga.com Document Security Systems, Inc. and CardLogix Form Partnership
- benzinga.com Biotech /Pharma Market Movers; (NYSE:BSX), (NASDAQ:BPAX), (OTCBB: UVFT), (NASDAQ: CELG)
- benzinga.com Biotech /Pharma Sector Trading Snapshot; (NASDAQ:BPAX, CADX, SUPG,)(UVFT.OB)
- benzinga.com Biotech/Pharma Stock Profile Update; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
- benzinga.com BPAX Reaches Key LibiGel® Safety Study Enrollment Target
- benzinga.com BioSante Pharmaceuticals Reaches Safety Study Enrollment Target
- benzinga.com Data Monitoring Committee Unanimously Recommends Continuation of Celsion's Phase III ThermoDox® HEAT Study
- benzinga.com Dell Exceeds Expectations - Analyst Blog
benzinga.com Another Setback for Sutent - Analyst Blog - benzinga.com JMP Securities Bullish on Pharmasset, Inc. (NASDAQ: VRUS)
- benzinga.com VRUS' RG7128 Emerging as Vital Class of Nucleoside HCV Polymerase Inhibitors
- benzinga.com FNX Earns $12.5 Million in Second Quarter TORONTO, ONTARIO--(Marketwire - Aug. 14, 2009) - FNX Mining Company Inc. (TSX:FNX) ("FNX" or the "Company") reports financial and operational results for the quarter ending June 30, 2009 for its…
- benzinga.com Denison Mines Corp. Reports Second Quarter Earnings TORONTO, ONTARIO--(Marketwire - Aug. 12, 2009) - Denison Mines Corp. ("Denison" or the "Company") (TSX:DML)(NYSE Amex:DNN) today reported its financial results for the three months and six months…
- benzinga.com Antisoma announces discontinuation of development of AS1402 LONDON and CAMBRIDGE, MA--(Marketwire - August 7, 2009) - Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that the phase II trial of AS1402 in breast cancer is to be discontinued. This follows…